Hypertension for the PEBC® Exam: Canadian Guidelines and Practice Questions

Hypertension is one of the most heavily tested chronic conditions on the PEBC® Pharmacist Qualifying Examination Part I. Under Blueprint Ver. 03-2026, Clinical Care makes up about half of the exam, and blood pressure cases are a natural fit: you have to confirm the diagnosis, decide whether drug therapy is warranted, pick a regimen, and monitor it safely. See the exam guide for how the blueprint is weighted.

This page follows the 2025 Hypertension Canada primary care guideline, which simplified Canadian practice around a single threshold, a single systolic target and early combination therapy. Many popular review books still teach older Canadian numbers or US staging, so pay attention to where the current Canadian approach differs.

Last reviewed October 18, 2026 · Based on the Pharmacist Qualifying Examination Blueprint, Ver. 03-2026

Diagnosis, treatment thresholds and targets

Measure with a validated automated device using standardized technique (seated, back supported, arm at heart level, correct cuff, no talking). Confirm an elevated office reading with out-of-office measurement (home or 24 hour ambulatory monitoring), which also uncovers white coat and masked hypertension. For home monitoring, a common Canadian protocol is duplicate readings morning and evening for one week.

The 2025 guideline uses the same 130/80 mmHg threshold for automated office, home and daytime ambulatory readings. Earlier Canadian guidance used 135/85 mmHg for automated office and home readings, which is a frequent source of wrong answers.

Key numbers in the 2025 Hypertension Canada primary care guideline
DecisionCurrent Canadian approach
Hypertension defined as130/80 mmHg or higher (validated device, confirmed out of office)
Start drug therapy140/90 mmHg or higher, OR systolic 130 to 139 mmHg with high cardiovascular risk
High cardiovascular riskEstablished cardiovascular disease, age 75 or older, chronic kidney disease, diabetes, or 10 year Framingham risk of 20% or more
Systolic 130 to 139 mmHg, not high riskLifestyle changes, then reassess BP and risk in 3 to 6 months
Treatment targetSystolic below 130 mmHg if tolerated (no separate diastolic target)

First-line and add-on therapy

Lifestyle advice applies to everyone: sodium reduction, a DASH style diet, regular physical activity, weight management, limiting alcohol and stopping smoking. When drugs are indicated, the guideline moves straight to low-dose combination therapy, ideally as a single pill, regardless of how high the starting BP is.

  • Beta-blockers are not first-line for uncomplicated hypertension. Reserve them for a compelling indication such as heart failure with reduced ejection fraction, angina, post myocardial infarction or rate control in atrial fibrillation.
  • ACE inhibitors and ARBs are treated as interchangeable for BP control. An ARB avoids ACE inhibitor cough. Never combine an ACE inhibitor with an ARB (or aliskiren).
  • Common Canadian products: ramipril (Altace), perindopril (Coversyl), perindopril/indapamide (Coversyl Plus), candesartan (Atacand), telmisartan/amlodipine (Twynsta), indapamide (Lozide), chlorthalidone (generic), nifedipine XL (Adalat XL).
  • Patients already controlled on another regimen do not need to be switched to the preferred single pill.
  1. Step 1: a low-dose single-pill combination of two of three complementary classes: an ACE inhibitor or ARB, a thiazide or thiazide-like diuretic, and a long-acting dihydropyridine calcium channel blocker. The primary care algorithm names irbesartan/hydrochlorothiazide (Avalide) as its preferred example because of cost and availability.
  2. Step 2: if above target, add the third class (for example amlodipine, Norvasc) to make ACE inhibitor or ARB plus diuretic plus CCB, titrating to maximally tolerated doses.
  3. Step 3: if still above target on all three, add spironolactone (Aldactone), after confirming adherence, technique and interfering drugs.

Monitoring

  • Baseline workup after diagnosis: electrolytes, creatinine and eGFR, fasting glucose or A1C, lipids, urinalysis and urine albumin to creatinine ratio, and an ECG. These results feed the high risk assessment.
  • Recheck potassium and creatinine after starting or increasing an ACE inhibitor, ARB, diuretic or spironolactone. A small rise in creatinine after starting RAAS blockade is expected; a large rise or hyperkalemia needs action.
  • Thiazides: watch for hypokalemia, hyponatremia, hyperuricemia (gout flares) and glucose changes. Dihydropyridine CCBs: ankle edema, flushing, headache.
  • Encourage home BP monitoring with a validated device and review the log at follow-up visits until the target is reached.

Special populations

Older adults

There is no age-based relaxed target in the 2025 guideline. Most older adults benefit from the same systolic goal, but individualize for frailty, falls, symptomatic orthostatic hypotension and goals of care. Being 75 or older counts as high cardiovascular risk.

Diabetes and chronic kidney disease

Both count as high risk, so drug therapy starts at a systolic of 130 mmHg. An ACE inhibitor or ARB is preferred when albuminuria is present. See the diabetes review for the Diabetes Canada approach to cardiorenal protection, including SGLT2 inhibitors.

Pregnancy

Pregnancy is outside the scope of the primary care guideline; Canadian practice follows the SOGC. ACE inhibitors, ARBs and direct renin inhibitors are contraindicated (fetal renal toxicity), so switch before conception when possible. Oral options include labetalol (Trandate), long-acting nifedipine and methyldopa.

Red flags and when to refer

  • Markedly elevated BP (for example 180/110 mmHg or higher) with chest pain, shortness of breath, neurological symptoms, confusion or vision changes suggests a hypertensive emergency: send to emergency care.
  • Clues to secondary hypertension: onset at a young age, sudden worsening, unprovoked hypokalemia (consider primary aldosteronism), resistant hypertension, or episodic headache, palpitations and sweating.
  • Drug causes to screen for at the counter: NSAIDs, oral decongestants, combined hormonal contraceptives, corticosteroids, stimulants, venlafaxine, licorice and high sodium effervescent products.

Common exam traps

  • Using 140/90 mmHg as the diagnostic threshold. In 2025 Canada, 140/90 mmHg is the drug treatment threshold for patients who are not high risk; diagnosis starts at 130/80 mmHg.
  • Quoting the old 135/85 mmHg home and automated office cut-off, or applying US stage 1 and stage 2 labels.
  • Choosing high-dose monotherapy when a low-dose single-pill combination is the preferred initial step.
  • Picking a beta-blocker as first-line therapy without a compelling indication.
  • Adding an ARB to an ACE inhibitor for resistant hypertension instead of adding the missing class or spironolactone.
  • Continuing an ACE inhibitor or ARB in a patient who is pregnant or planning pregnancy.
  • Setting a diastolic target, or automatically relaxing the target because a patient is over 80.

Practice questions

Original questions written for this page. Answer each one before you open the explanation.

Question 1Hypertension
Providing Care: Clinical Care

A 49-year-old man was found to have an office BP of 152/94 mmHg. A week of home readings with a validated device averages 146/92 mmHg. He has no diabetes, kidney disease or cardiovascular disease, and his baseline labs are normal. He has already started reducing sodium and walking daily.

According to the 2025 Hypertension Canada primary care guideline, which is the most appropriate initial drug therapy?

  1. A.Continue lifestyle changes alone and reassess in 6 months
  2. B.Atenolol 50 mg once daily
  3. C.A low-dose single-pill combination such as irbesartan/hydrochlorothiazide
  4. D.Ramipril plus candesartan
  5. E.Hydralazine 25 mg four times daily
Show answer and explanation

Answer: C

His confirmed BP is above 140/90 mmHg, so drug therapy is indicated even though he is not high risk. The 2025 guideline recommends starting with a low-dose combination of two of the three first-line classes, ideally as a single pill, and irbesartan/hydrochlorothiazide is the algorithm's preferred example.

Why the other options are wrong

  • A:Lifestyle alone with reassessment applies to systolic 130 to 139 mmHg without high risk. At 146/92 mmHg drug therapy is recommended.
  • B:Beta-blockers are not first-line for uncomplicated hypertension because they are less protective against stroke and less well tolerated.
  • D:Combining an ACE inhibitor with an ARB adds hyperkalemia and kidney injury risk without cardiovascular benefit.
  • E:Hydralazine is not a first-line agent, causes reflex tachycardia and fluid retention, and four times daily dosing harms adherence.

Reference: Hypertension Canada 2025 Primary Care Guideline (CMAJ 2025)

Question 2Hypertension
Providing Care: Clinical Care

A 52-year-old woman has a mean home BP of 134/82 mmHg over 7 days. She has no diabetes, chronic kidney disease or cardiovascular disease. Her 10 year Framingham risk is 8%. She asks whether she needs a prescription.

What is the most appropriate recommendation?

  1. A.Her BP is normal; no follow-up is needed
  2. B.Start amlodipine 5 mg daily to reach a target below 120/80 mmHg
  3. C.Start a low-dose single-pill combination today
  4. D.Intensify lifestyle changes and reassess BP and cardiovascular risk in 3 to 6 months
Show answer and explanation

Answer: D

A confirmed BP of 130/80 mmHg or higher meets the 2025 Canadian definition of hypertension. With a systolic of 130 to 139 mmHg and no high risk features, the guideline does not recommend drugs yet; it emphasizes lifestyle changes and reassessment of BP and risk in 3 to 6 months.

Why the other options are wrong

  • A:A home average of 134/82 mmHg is at or above 130/80 mmHg, so it meets the current Canadian definition of hypertension and needs follow-up.
  • B:Drug therapy is not recommended at this level without high cardiovascular risk, and the guideline target is systolic below 130 mmHg, not below 120/80 mmHg.
  • C:Pharmacotherapy at systolic 130 to 139 mmHg is reserved for high risk patients (cardiovascular disease, age 75 or older, CKD, diabetes or Framingham risk of 20% or more).

Reference: Hypertension Canada 2025 Primary Care Guideline (CMAJ 2025)

Question 3Hypertension
Providing Care: Clinical Care

A 63-year-old man takes irbesartan/hydrochlorothiazide 300/25 mg daily and amlodipine 10 mg daily. Pharmacy refill records and his pill organizer confirm good adherence, and he uses no NSAIDs or decongestants. His home BP averages 142/86 mmHg. Potassium is 4.2 mmol/L and eGFR is 68 mL/min/1.73 m².

Which is the most appropriate next step?

  1. A.Add spironolactone 12.5 to 25 mg daily and recheck potassium and creatinine
  2. B.Add metoprolol 50 mg twice daily
  3. C.Add ramipril 10 mg daily
  4. D.Switch amlodipine to diltiazem CD
Show answer and explanation

Answer: A

He is above target on maximally tolerated doses of all three first-line classes with adherence confirmed. The guideline suggests adding spironolactone at this point. His potassium and kidney function allow it, but they must be rechecked soon after starting because of hyperkalemia risk with concurrent ARB therapy.

Why the other options are wrong

  • B:Beta-blockers lower BP less than spironolactone in resistant hypertension and are reserved for a compelling indication, which he does not have.
  • C:Adding an ACE inhibitor to an ARB is dual RAAS blockade, which raises hyperkalemia and acute kidney injury risk without benefit.
  • D:Swapping one CCB for a non-dihydropyridine CCB does not add a new mechanism and diltiazem is less potent for BP lowering.

Reference: Hypertension Canada 2025 Primary Care Guideline (CMAJ 2025)

Question 4Hypertension in pregnancy
Providing Care: Clinical Care

A 31-year-old woman with chronic hypertension controlled on ramipril 5 mg daily calls the pharmacy. A home pregnancy test is positive and she estimates she is 6 weeks pregnant. Her BP this morning was 138/88 mmHg.

What is the most appropriate recommendation?

  1. A.Continue ramipril until the second trimester, then switch
  2. B.Stop ramipril and contact her prescriber promptly to start an alternative such as labetalol or long-acting nifedipine
  3. C.Switch ramipril to candesartan
  4. D.Stop ramipril and use no antihypertensive for the rest of the pregnancy
Show answer and explanation

Answer: B

ACE inhibitors and ARBs are contraindicated in pregnancy because of fetal kidney toxicity, so ramipril should be stopped as soon as pregnancy is recognized. Canadian obstetric guidance supports labetalol, long-acting nifedipine or methyldopa, and chronic hypertension still needs treatment and monitoring during pregnancy.

Why the other options are wrong

  • A:Fetal risk from RAAS blockade rises after the first trimester, so delaying the switch is the opposite of what is needed.
  • C:Candesartan is an ARB and carries the same fetal risk as an ACE inhibitor.
  • D:Chronic hypertension in pregnancy should be treated to protect the patient and fetus; stopping all therapy is unsafe.

Reference: SOGC Guideline No. 426: Hypertensive Disorders of Pregnancy (2022)

Question 5Hypertension
Providing Care: Clinical Care

A 58-year-old woman started perindopril/indapamide 2 months ago and her BP is now at target. She reports a persistent dry, tickly cough that started about 3 weeks after the medication. She has no fever, wheeze or other respiratory symptoms, and no history of angioedema.

What is the most appropriate recommendation?

  1. A.Switch to a different ACE inhibitor such as ramipril
  2. B.Add dextromethorphan syrup as needed
  3. C.Switch the ACE inhibitor component to an ARB, for example an ARB/thiazide single pill
  4. D.Stop all antihypertensives and monitor
Show answer and explanation

Answer: C

A dry cough is a class effect of ACE inhibitors caused by bradykinin accumulation. Switching to an ARB keeps the RAAS blockade and the combination approach while usually resolving the cough within weeks.

Why the other options are wrong

  • A:Cough is a class effect, so another ACE inhibitor is likely to cause it again.
  • B:Treating the side effect with a cough suppressant ignores the cause and is unlikely to work.
  • D:Her BP is controlled and she still needs treatment; the problem is one drug class, not therapy as a whole.

Reference: Hypertension Canada 2025 Primary Care Guideline (CMAJ 2025)

Practise more hypertension questions

Generate PEBC-style MCQs on hypertension, turn your own notes into flashcards and summary sheets, and ask the AI tutor to explain anything you got wrong. Free to start; paid plans add more question sets and unlimited tutor chat.

Start free, no credit cardSee plans

Frequently asked questions

What BP defines hypertension in Canada now?

The 2025 Hypertension Canada primary care guideline defines hypertension as 130/80 mmHg or higher measured with a validated device and confirmed out of office. The same number applies to automated office, home and daytime ambulatory readings.

Does every patient with hypertension need medication?

No. Drugs are recommended at 140/90 mmHg or higher, or at a systolic of 130 to 139 mmHg when cardiovascular risk is high. Otherwise lifestyle changes come first, with reassessment in 3 to 6 months.

Why does the exam favour single-pill combinations?

Canadian guidance has accepted single-pill combinations as first-line since 2017, and the 2025 guideline makes a low-dose two-drug single pill the default first step. It lowers BP faster than titrating one drug and simplifies adherence.

Where do beta-blockers fit?

Only when there is a specific indication such as heart failure with reduced ejection fraction, angina, prior myocardial infarction or rate control in atrial fibrillation. Otherwise they come after the three first-line classes and spironolactone. For AF rate control and stroke prevention, see the anticoagulation review.

More free PEBC resources

Sources

PharmaStudyAI is an independent study tool. It is not affiliated with, endorsed by, or connected to the Pharmacy Examining Board of Canada (PEBC®). PEBC® is a registered trademark of the Pharmacy Examining Board of Canada. Content is for exam study only and is not a substitute for clinical judgement or current product monographs.